Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Lymphoma, Mantle-Cell 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Heart Failure 1

Interventions

Brentuximab Vedotin 3relmacabtagene autoleucel 2fludarabine phosphate 2fludarabine 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 2xihuang 1tocilizumab 1tislelizumab 1sofosbuvir-velpatasvir drug combination 1sintilimab 1rasburicase 1ledipasvir 1entecavir 1apatinib 1aflibercept 1acalabrutinib 1Urate Oxidase 1Trabectedin 1Thiotepa 1Thalidomide 1Tenofovir 1Tamsulosin 1Sofosbuvir 1Sevoflurane 1Rivaroxaban 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recurrence × acalabrutinib × Clear all
NCT04930536 2024-11-22

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

AstraZeneca

Phase 4 Completed
103 enrolled 10 charts
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡